ASPIRIN AND DIPYRIDAMOLE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aspirin And Dipyridamole, and what generic alternatives are available?
Aspirin And Dipyridamole is a drug marketed by Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Glenmark Pharms Sa, Micro Labs, Par Pharm Inc, Sandoz, Sun Pharm, and Zydus Pharms. and is included in eleven NDAs.
The generic ingredient in ASPIRIN AND DIPYRIDAMOLE is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aspirin And Dipyridamole
A generic version of ASPIRIN AND DIPYRIDAMOLE was approved as aspirin; dipyridamole by BARR on August 14th, 2009.
Summary for ASPIRIN AND DIPYRIDAMOLE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 10 |
Clinical Trials: | 25 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in ASPIRIN AND DIPYRIDAMOLE? | ASPIRIN AND DIPYRIDAMOLE excipients list |
DailyMed Link: | ASPIRIN AND DIPYRIDAMOLE at DailyMed |
Recent Clinical Trials for ASPIRIN AND DIPYRIDAMOLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rutgers, The State University of New Jersey | Phase 3 |
Ministry of Health, France | Phase 3 |
University Hospital, Lille | Phase 3 |
Pharmacology for ASPIRIN AND DIPYRIDAMOLE
Drug Class | Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor |
Mechanism of Action | Cyclooxygenase Inhibitors |
Physiological Effect | Decreased Platelet Aggregation Decreased Prostaglandin Production |